Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy

Baoheng Gui; Yingxin Zhang; Bo Liang; Yvonne  Ka Yin Kwok; Wai Ting Lui; Queenie  Sum Yee Yeung; Lingyin Kong; Liming Xuan; Jacqueline  Pui Wah Chung; Kwong Wai Choy

doi:10.3791/59273

JoVE Journal > Genetics

유전학

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy

Published: August 25, 2019

doi:

10.3791/59273

Baoheng Gui*^1,2,3, Yingxin Zhang*⁴, Bo Liang⁵, Yvonne Ka Yin Kwok⁴, Wai Ting Lui⁴, Queenie Sum Yee Yeung⁴, Lingyin Kong⁶, Liming Xuan⁶, Jacqueline Pui Wah Chung⁴, Kwong Wai Choy^3,4

¹Department of Genetics and Metabolism,Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, ²Birth Defects Prevention and Control Institute of Guangxi Zhuang Autonomous Region, ³Shenzhen Research Institute,The Chinese University of Hong Kong, ⁴Department of Obstetrics and Gynaecology,The Chinese University of Hong Kong, ⁵State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic and Developmental Sciences, School of Life Sciences and Biotechnology,Shanghai Jiao Tong University, ⁶Basecare Medical Device Co., Ltd

Summary

Here, we introduce a semiconductor sequencing method for preimplantation genetic testing for aneuploidy (PGT-A) with the advantages of short turnaround time, low cost, and high throughput.

Abstract

Chromosomal aneuploidy, one of the main causes leading to embryonic development arrest, implantation failure, or pregnancy loss, has been well documented in human embryos. Preimplantation genetic testing for aneuploidy (PGT-A) is a genetic test that significantly improves reproductive outcomes by detecting chromosomal abnormalities of embryos. Next-generation sequencing (NGS) provides a high-throughput and cost-effective approach for genetic analysis and has shown clinical applicability in PGT-A. Here, we present a rapid and low-cost semiconductor sequencing-based NGS method for screening of aneuploidy in embryos. The first step of the workflow is whole genome amplification (WGA) of the biopsied embryo specimen, followed by construction of sequencing library, and subsequent sequencing on the semiconductor sequencing system. Generally, for a PGT-A application, 24 samples can be loaded and sequenced on each chip generating 60−80 million reads at an average read length of 150 base pairs. The method provides a refined protocol for performing template amplification and enrichment of sequencing library, making the PGT-A detection reproducible, high-throughput, cost-efficient, and timesaving. The running time of this semiconductor sequencer is only 2−4 hours, shortening the turnaround time from receiving samples to issuing reports into 5 days. All these advantages make this assay an ideal method to detect chromosomal aneuploidies from embryos and thus, facilitate its wide application in PGT-A.

Introduction

Choosing good-quality viable embryos with normal chromosome copy numbers (euploid) for transfer in assisted reproduction helps to improve pregnancy outcomes. Traditionally, the well-established morphological grading system is widely used for embryo evaluation due to its easy availability and non-invasive nature. However, it has been shown that morphological assessment can only provide limited information on embryo quality¹ and implantation potential². One fundamental reason is its inability in evaluating the chromosomal composition of the embryos.

Chromosomal aneuploidy (abnormal copy number of chromosomes) is one of the main causes leading to embryonic development arrest, implantation failure or pregnancy loss. The occurrence of aneuploidy has been well documented in human embryos, accounting for 60%−70% in cleavage-stage embryos³^,⁴ and 50%−60% in blastocysts⁵. This, to some extent, has contributed to the bottleneck in improving the pregnancy rate of in-vitro fertilization (IVF) treatment, which has maintained at around 35%−40%⁶^,⁷. Therefore, selecting euploid embryos for transfer is believed to be beneficial for improving pregnancy outcomes. To this end, preimplantation genetic testing for aneuploidy (PGT-A) has been further developed to investigate embryo viability using genetic approaches. There are increasing numbers of randomized controlled trials and cohort studies supporting the crucial role of PGT-A. It has been proved that the application of PGT-A decreases the miscarriage rate and increases clinical pregnancy rate and implantation rate⁸, ongoing pregnancy rate and live birth rate⁹.

Historically, different methods have been applied in PGT-A, such as fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), array-CGH, and single nucleotide polymorphism (SNP)-microarray. Previous studies have indicated that PGT-A for cleavage-stage embryos by FISH yields results that are poorly consistent with those obtained by comprehensive chromosomal screening (CCS) of corresponding blastocysts using 59273array-CGH or SNP-microarray59273¹⁰. These discrepancies can be attributed to chromosomal mosaicism, FISH technical artifacts, or embryonic self-correction of chromosomal segregation errors during development¹¹. It has been widely recognized that using blastocyst trophectoderm (TE) biopsies for array-based PGT-A such as array-CGH or SNP-microarray is effective for identifying the chromosomal imbalance in embryos¹⁰^,¹². Recently, single-cell next-generation sequencing (NGS) provides a high-throughput and cost-effective approach for genetic analysis and has shown clinical applicability in PGT-A¹³^,¹⁴^,¹⁵, which make it a promising alternative to currently available methods.

Here, we present a fast, robust, and low-cost semiconductor sequencing-based NGS method for screening of aneuploidy in human embryos. The first step of the workflow is whole genome amplification (WGA) of the biopsied embryo specimen, using a single-cell WGA kit, followed by construction of sequencing library, and subsequent sequencing on the semiconductor sequencing system.

Through detecting the H⁺ ions that are released from each deoxyribonucleoside triphosphate incorporation during DNA strand synthesis, the system transfers the chemical signals (pH change) captured by the semiconductor elements to direct digital data, which are further interpreted into DNA sequence information. Eliminating the requirement for expensive optical detection and complex sequencing reactions, this simple sequencing chemistry reduces total reagent cost and shortens the sequencing running time into 2−4 hours¹⁶. More importantly, based on the manufacturer’s performance specifications, the semiconductor sequencing platform can generate up to 15 GB sequencing data (depends on the quality of library) per run, which is significantly higher than some of the other sequencers producing only around 3−4 GB data (with 2 x 75 bp read length)¹⁷. In clinical applications of PGT-A, this platform can achieve 24 samples per chip generating up to 80 million reads¹⁷ and at least one million unique reads of each sample. The read depth can ensure that each sample has at least 0.05x whole genome coverage. The above advantages of this platform make it an ideal screening method and thus, facilitate its wide applications in PGT-A¹⁸.

Protocol

Ethical approval was granted by the Joint Chinese University of Hong Kong―New Territories East Cluster Clinical Research Ethics Committee (Reference Number: 2010.432). Research license was approved by the Council on Human Reproductive Technology of Hong Kong (Number R3004).

1. Whole genome amplification

Prior to start, check the volume of magnetic beads (Table of Materials) to ensure that there is no less than 135 µL (with a 20% excess) for each sample. Keep the magnetic beads at room temperature (RT) for at least 30 min. Prepare 720 µL (with a 20% excess) of 70% ethanol for each sample. Equip a thermal cycler (Table of Materials) with heated lid at 105 °C.
NOTE: The newly prepared 70% ethanol (Table of Materials) should be used up within 3 days.
Sample preparation
NOTE: In the routine practice, 5 to 10 trophectoderm cells of the blastocyst are biopsied according to the practice guideline¹⁹.
1. Suspend biopsies in 2 µL of 1x phosphate-buffered saline (PBS) in a single 0.2 mL polymerase chain reaction (PCR) tube.
2. Briefly spin the tube on a mini centrifuge for 3 s to collect the droplets.
Cell lysis and extraction
1. Thaw the cell extraction buffer (Table of Materials) and the extraction enzyme dilution buffer (Table of Materials) on ice, vortex and briefly spin on a mini centrifuge for 3 s before use.
2. Add 3 µL of cell extraction buffer to each tube from step 1.2.2.
3. Prepare a 5 µL cell lysis master mix for each sample by adding 4.8 µL of extraction enzyme dilution buffer and 0.2 µL cell extraction enzyme (Table of Materials). Mix well and aliquot into each tube from step 1.3.2. Flip the tube gently and briefly spin on a mini centrifuge for 3 s.
  NOTE: tips should not touch the liquid containing the cell samples when adding the master mix.
4. Incubate the tube from step 1.3.3 in the thermal cycler with heated lid. Run the program with the following settings: 10 min at 75 °C, 4 min at 95 °C, hold at 4 °C.
Preamplification
1. Thaw the preamplification buffer (Table of Materials) on ice, vortex and briefly spin on a mini centrifuge for 3 s before use.
2. Prepare a 5 µL preamplification master mix for each sample by adding 4.8 µL of preamplification buffer and 0.2 µL of preamplification enzyme (Table of Materials). Mix well and aliquot into each tube from step 1.3.4. Flip the tube gently and briefly spin on a mini centrifuge for 3 s.
  NOTE: Tips should not touch the liquid containing the DNA samples when adding the master mix.
3. Incubate the tube in the thermal cycler with heated lid. Run the program with the flowing settings: 2 min at 95 °C; 12 cycles for 15 s at 95 °C, 50 s at 15 °C, 40 s at 25 °C, 30 s at 35 °C, 40 s at 65 °C, 40 s at 75 °C; hold at 4 °C.
Amplification
1. Thaw the amplification buffer (Table of Materials) on ice, vortex and briefly spin on a mini centrifuge for 3 s before use.
2. Prepare a 60 µL amplification master mix for each sample by adding 25 µL of amplification buffer, 0.8 µL of amplification enzyme (Table of Materials), and 34.2 µL of nuclease-free water for WGA (Table of Materials). Mix well and aliquot into each tube from step 1.4.3. Flip the tube gently and briefly spin on a mini centrifuge for 3 s.
3. Incubate the tube in the thermal cycler with heated lid. Run the program with the following settings: 2 min at 95 °C; 14 cycles for 15 s at 95 °C, 1 min at 65 °C, 1 min at 75 °C; hold at 4 °C.
Purification of the WGA products
1. Transfer each WGA product from step 1.5.3 into new 1.5 mL tubes. Add 112.5 µL of magnetic beads into each tube. Vortex and incubate at RT for 5 min.
  NOTE: Completely mix the magnetic beads before use.
2. Place the tubes onto a magnetic stand (Table of Materials) for 3 min until the supernatant is clear. Discard all the supernatant without disturbing the beads.
3. Add 300 µL of 70% ethanol to each tube. Rotate each tube 180° to let the beads run through the ethanol and rotate back to the original position. Discard all the supernatant after the beads have settled without disturbing the beads. Repeat this step once.
  NOTE: Keep the tube on the magnetic stand while rotating the tube horizontally.
4. Briefly spin each tube on a mini centrifuge for 3 s. Place the tubes onto the magnetic stand until the residual supernatant is clear. Discard all the residual supernatant without disturbing the beads. Air dry the beads at RT for approximately 3 min.
5. Remove the tubes from the magnetic stand and resuspend the dried beads by adding 35 µL of low Tris-EDTA (TE) buffer (Table of Materials). Incubate at RT for 5 min.
6. Place the tubes onto the magnetic stand for 3 min until the supernatant is clear. Transfer all the supernatant containing eluted DNA to new 1.5 mL tubes without disturbing the beads.

2. Quality control of the WGA products

Quantify each purified WGA product from step 1.6.6 by a fluorometer assay (Table of Materials) according to the manufacturer’s manual using 1 µL of WGA product as starting material.
NOTE: The accepted concentration of the WGA product is ≥ 10 ng/µL. Any product below this threshold is not recommended to proceed to the next steps.

3. Fragmentation of WGA products

Prior to start, preheat a dry block heater to 37 °C. Prepare 6 µL (with a 20% excess) of 0.5 M EDTA for each sample. Based on the concentration, aliquot 300 ng of DNA from each purified WGA product in step 1.6.6 to new 0.2 mL PCR tubes and bring volume to 16 µL with nuclease-free water for each tube.
Fragmentation
1. Prepare a 4 µL double stranded DNA (dsDNA) fragmentation reaction mix for each sample by adding 2 µL of dsDNA fragmentation reaction buffer (Table of Materials) and 2 µL of dsDNA fragmentation enzymes (Table of Materials). Mix well and aliquot into each tube from step 3.1. Vortex and briefly spin on a mini centrifuge for 3 s. Incubate the tubes for 25 min at 37 °C in a thermal cycler with heated lid.
2. Add 5 µL of 0.5 M EDTA immediately to each tube. Mix well by vortexing and briefly spin on a mini centrifuge for 3 s.
Purification and resuspension
1. Transfer each product from step 3.2.2 into new 1.5 mL tubes. Add 37.5 µL of magnetic beads to each tube. Mix by vertexing and incubate at RT for 5 min.
2. Purify the products as described from step 1.6.2 to step 1.6.4.
3. Elute each purified product as described in steps 1.6.5 and 1.6.6 by adding 32 µL of low-TE buffer.

4. Library construction

Blunt-end repairment, size selection and purification
1. Prepare a 20 µL blunt-end repairment mix for each sample by adding 9.5 µL of nuclease-free water, 10 µL of 5x end repair buffer (Table of Materialstube from step 3.3.3. Vortex and briefly spin on a mini centrifuge for 3 s.
2. Add 50 µL of magnetic beads to each tube from step 4.1.1. Vortex and incubate at RT for 5 min.
  NOTE: Completely mix the magnetic beads before use.
3. Place each tube onto the magnetic stand for 3 min until the supernatant is clear. Transfer all the supernatant to new 1.5 mL tubes where 25 µL magnetic beads are added for each. Vortex the tubes with the transferred supernatant and incubate at RT for 5 min.
4. Purify the products in the incubated tubes as described from step 1.6.2 to step 1.6.4.
5. Elute each purified product as described in steps 1.6.5 and 1.6.6 by adding 32 µL of low-TE buffer.
  NOTE: This is a safe stop point; the purified DNA from this step is stable at 4 °C for no more than 24 h.
Adaptor ligation and purification
1. Prepare a 17 µL adapter ligation mix for each sample by adding 10 µL of nuclease-free water, 5 µL of 10x ligase buffer (Table of Materials), 1 µL of P1 adapter (Table of Materials), and 1 µL of DNA ligase (Table of Materials). Mix well by vortexing for 5 s and spin on a mini centrifuge for 15 s, and aliquot into each tube from step 4.1.5.
2. Add 1 µL of adapters (Table of Materials) to each tube from step 4.2.1 according to the sample sheet (Supplemental File: Sample sheet for adapter ligation). Vortex and briefly spin on a mini centrifuge for 3 s. Incubate the tubes at RT (20−25 °C) for 20 min.
3. Add 75 µL of magnetic beads to each tube from step 4.2.2. Mix by vertexing and incubate at RT for 5 min. Then, purify the products as described from step 1.6.2 to step 1.6.4.
4. Elute each purified product as described in steps 1.6.5 and 1.6.6 by adding 15 µL of low-TE buffer. Transfer all the supernatant containing eluted DNA to new 0.2 mL 8-tube strips.
  NOTE: This is a safe stop point; the purified DNA from this step is stable at 4 °C for no more than 24 h.
Amplification and purification
1. Prepare a 50 µL amplification master mix for each sample by adding 47.5 µL of super mix (Table of Materials) and 2.5 µL of primer mix (Table of Materials). Mix well by vortexing and briefly spin on a mini centrifuge, and aliquot into the 0.2 mL 8-tube strips from step 4.2.4.
2. Vortex the strips for 30 s and briefly spin on a mini centrifuge for 3 s. Incubate the strips in the thermal cycler with heated lid. Run the program with the following settings: 20 min at 72 °C; 5 min at 95 °C; 10 cycles for 15 s at 95 °C, 15 s at 62 °C, 1 min at 70 °C; 5 min at 70 °C; hold at 4 °C.
3. Transfer each product from step 4.3.2 into new 1.5 mL tubes. Add 97.5 µL of magnetic beads to each tube. Mix by vortexing and incubate at RT for 5 min.
4. Purify the products as described from step 1.6.2 to step 1.6.4.
5. Elute each purified product as described in steps 1.6.5 and 1.6.6 by adding 25 µL of low-TE buffer.

5. Quality control and dilution of the DNA library

Quantify each prepared DNA library from step 4.3.5 by the fluorometer assay according to the manufacturer’s manual using 2 µL of DNA library as starting material.
The accepted concentration of the DNA library is ≥ 0.5 ng/µL and that of the positive control (Table of Materials) is ≤ 15 ng/µL. If the concentration of the positive control varies too much from 15 ng/µL, repeat the quantification of the positive control until the concentration is close to 15 ng/µL. If the concentration of the library is below 0.5 ng/µL, restart from fragmentation (section 3).
NOTE: Ensure that the concentration of the positive control reaches the accepted value before quantifying the DNA library.
Dilute each library to 100 pmol by adding nuclease-free water. Add 1 µL of library to n µL of nuclease-free water; calculate n using the equation below:

where Q is the concentration of each library measured by the fluorometer assay and C is the concentration of the positive control measured by the fluorometer assay.

6. Sequencing

Prior to start, prepare 48 µL (with a 20% excess) of 1 M NaOH for each sample and one nuclease-free 1.5 mL tube. Thaw the master mix PCR buffer (Table of Materials) (2000 µL in volume) at RT. Bring the sphere particles (Table of Materials) to RT.
Library pooling
1. Vortex each diluted library from step 5.3 and briefly spin 4x on a mini centrifuge for 3 s each time. Take 5 µL of each library to pool into the nuclease-free 1.5 mL tube. Vortex the mixed library and briefly spin on a mini centrifuge for 3 s.
Emulsion PCR using an emulsion system
1. Add 150 µL of breaking solution to 2 new recovery tubes (Table of Materials). Install the new recovery tubes, recovery router and amplification plate.
2. Mix by inverting the oil bottle (Table of Materials) 3 times. Ensure that both the oil and recovery solution (Table of Materials) are at least 2/3 full.
3. Vortex the master mix PCR buffer for 30 s and briefly spin on a mini centrifuge for 3 s. Vortex the sphere particles and the mixed library from step 6.2.1 for 1 min and briefly spin on a mini centrifuge for 3 s.
4. Prepare a 2400 µL ligation mix by adding 172 µL of nuclease-free water, 8 µL of mixed library from step 6.3.3, 120 µL of enzyme mix (Table of Materials), and 100 µL of sphere particles to the tube containing 2000 µL master mix PCR buffer.
5. Set a pipette to 800 µL. Load the ligation mix from step 6.3.4 to the reaction filter (Table of Materials) through the sample port. Use a 1000P pipette to add 200 µL of reaction oil to the reaction filter.
6. Select the program Proton: Ion PI Hi-Q OT2 200 Kit, and then, select Assisted button to ensure that the device has been set up correctly by following the instructions on the monitor. Then, click Next to start the program.
Enrichment by an automatic enrichment system
1. When the emulsion PCR program is completed, click Next, and then click Final Spin to spin for 10 min. Take out the 2 recovery tubes after clicking Open Lid.
2. Discard the supernatant from the 2 recovery tubes until 100 µL remains in each tube, and label accordingly. Mix the solution well and transfer to a new 1.5 mL tube.
3. Add 200 μL of nuclease-free water to each recovery tube, wash by pipetting up and down several times, and transfer all the solution to the 1.5 mL tube in step 6.4.2. Repeat the wash step once.
4. Add 200 µL of nuclease-free water to one of the recovery tubes and wash by pipetting up and down several times. Transfer all the solution to the other recovery tube and wash by pipetting up and down several times. Then, transfer all the solution to the same 1.5 mL tube from step 6.4.3. Vortex the 1.5 mL tube for 30 s and centrifuge for 8 min at 15,500 x g.
  NOTE: The final total volume of the emulsion PCR product in this step should be approximately 1200 µL.
5. Discard the supernatant in the tube and keep 20 µL of the emulsion PCR product. Add 80 µL of resuspension solution (Table of Materials) to the tube. Mix by pipetting up and down.
6. Prepare a 320 µL melt-off solution for each chip by adding 280 µL of polyethylene glycol sorbitan monolaurate solution (Table of Materials) and 40 µL of 1 M NaOH.
  NOTE: 1 M NaOH should be stored at 4 °C or freshly prepared. Vortex before use.
7. Vortex the tube containing C1 beads (Table of Materials) for 30 s. Take 100 µL of C1 beads to a new 1.5 mL tube. Place the 1.5 mL tube onto the magnetic stand for 2 min at RT. Discard all the supernatant after the beads have settled without disturbing the beads.
8. Add 1 mL of wash solution C1 (Table of Materials) to the tube from step 6.4.7. Vortex for 30 s. Place the tube onto the magnetic stand for 2 min at RT. Discard all the supernatant after the beads have settled without disturbing the beads. Resuspend the beads by adding 130 µL of bead capture solution (Table of Materials).
9. Enrichment system (ES) setup
  1. Load the sample (100 µL emulsion PCR product) from step 6.4.5, the washed beads (130 µL) from step 6.4.8, ES wash solution (300 µL) (Table of Materials), and melt-off solution (300 µL) from step 6.4.6 into the 8-tube strip. The layout order is: sample (tube 1), washed beads (tube 2), ES wash solution (tubes 3, 4, 5), and melt-off solution (tube 7). Keep tubes 6 and 8 empty.
  2. Place the 8-tube strip from step 6.4.9.1 onto the ES. Install a pipette tip and a new 0.2 mL tube and start the program.
    NOTE: Ensure that pipetting works normal.
10. Wash the sphere particles after the enrichment is completed.
  1. Centrifuge the 0.2 mL tube from step 6.4.9.2 for 5 min at 15,500 x g. Discard the supernatant and keep 10 µL of the enrichment product. Add 200 µL of nuclease-free water to the tube. Mix by vortexing.
  2. Centrifuge the 0.2 mL tube from for 5 min at 15,500 x g. Discard the supernatant and keep 10 µL of the enrichment product. Add 90 µL of nuclease-free water to the tube. Mix by vortexing.
Template preparation
1. Vortex the positive control and spin briefly. Add 5 µL of positive control to the 100 µL template (the enrichment product from step 6.4.10.2). Vortex and centrifuge for 5 min at 15,500 x g. Discard the supernatant and keep 10 µL of the template.
2. Add 20 µL of sequencing primer (Table of Materials) and 15 µL of annealing buffer (Table of Materials) to the template tube from step 6.5.1. Vortex the tube and briefly spin on a mini centrifuge for 3 s.
3. Incubate the tube from step 6.5.2 in the thermal cycler with heated lid. Run the program with the following settings: 2 min at 95 °C, 2 min at 37 °C, hold at 4 °C.
4. Add 10 µL of loading buffer (Table of Materials) to the tube from step 6.5.3. Mix by pipetting up and down.
Sequencer initialization
1. Check the tank pressure of nitrogen gas (total pressure ≥ 500 psi, output pressure ≥ 10 psi, optimum 20-30 psi). Top-up 100 mL deionized water (18.2 MΩ) to C1 and C2 tubes (Table of Materials) and install them to corresponding C1 and C2 positions on the sequencer.
2. Prepare W1 (32 µL of 1 M NaOH) and W3 (40−50 mL of W3 buffer [Table of Materials]) solutions. Prepare W2 solution by adding 1920 mL of deionized water (18.2 MΩ), a whole bottle of W2 buffer (Table of Materials) and 8−12 µL of 1 M NaOH, and invert 4−8 times to mix.
  NOTE: Because the water quality varies geologically, adjust the volume of 1 M NaOH as needed. The starting pH of W2 is 5.9−6.1, and the optimal range after adjustment is 7.4−7.6. Change and install new reagent tubes and use lately used chip for washing.
3. Prepare the 4 new empty tubes from the sequencing supplement kit (Table of Materials). Label the 4 tubes as dGTP, dCTP, dATP, and dTTP, and add 70 µL of dGTP, dCTP, dATP, or dTTP (Table of Materials) to the corresponding tube (i.e., 70 µL dGTP to the tube labeled as dGTP, etc.). Vortex the tubes before use. Install the tubes to the corresponding positions designated on the sequencer (Table of Materials).
Chip wash
1. Wash the chip (Table of Materials) once by injecting 100 µL of isopropanol into the loading well of the chip. Remove the expelled liquid from the opposite well.
2. Wash the chip twice by injecting 100 µL of nuclease-free water into the loading well of the chip. Remove the expelled liquid from the opposite well.
3. Wash the chip once by injecting 100 µL of 0.1 M NaOH into the loading well of the chip. Remove the expelled liquid from the opposite well. Incubate at RT for 1 min.
4. Wash the chip once by injecting 100 µL of nuclease-free water into the loading well of the chip. Remove the expelled liquid from the opposite well.
5. Wash the chip twice by injecting 100 µL of isopropanol into the loading well of the chip. Remove the expelled liquid from the opposite well. Dry by blowing nitrogen onto the chip. Keep away from light.
Sample loading and sequencing
1. Mix the 55 µL sample from step 6.5.4 by pipetting up and down and load the sample to the loading well of the chip.
  NOTE: Keep the pipette tip and the 0.2 mL PCR tube used in this step.
2. Place the chip onto the chip mini centrifuge (Table of Materials) when
3. Prepare two new 1.5 mL tubes for the annealing buffer and flushing solution. Prepare the 50% annealing buffer by adding 500 µL of annealing buffer and 500 µL of nuclease-free water. Prepare the flushing solution by adding 500 µL of annealing buffer and 500 µL of 100 % 2-propanol.
4. Prepare two new 1.5 mL tubes and prepare the foaming mixture by mixing 49 µL of 50% annealing buffer and 1 µL of foaming solution (Table of Materials) in both tubes.
5. Set a pipette to 100 µL. Make bubbles by pipetting air into the foaming mixture from one of the two tubes from step 6.8.4. Make > 120 µL of bubbles and keep pipetting until no outstanding visible bubbles can be seen. Load 120 µL of bubbles into the loading well.
  NOTE: Ensure that there are no outstanding visible bubbles. Otherwise, start it over.
6. Transfer the excessive expelled liquid from the exit well from step 6.8.5 to the loading well by pipetting. Do not pipette bubbles. Centrifuge the chip for 30 s on the chip mini centrifuge.
7. Repeat step 6.8.5 by using the second tube containing the foaming mixture from step 6.8.4.
8. Add 55 µL of the 50% annealing buffer to the 0.2 mL tube kept in step 6.8.1. Use the kept pipette tip in step 6.8.1 to pipette up and down. Load all the 55 µL annealing buffer to the loading well. Centrifuge the chip for 30 s on the designated chip mini centrifuge.
9. Load 100 µL of flushing solution into the chip loading well and discard the expelled liquid from exit well. Repeat this loading step once.
  NOTE: If there are bubbles in the chip, expel small bubbles by big bubbles and flush by flushing solution. This can be achieved by pipetting 100 µL of flushing solution and leaving 5 µL of air below the flushing solution. Therefore, when pipetting the 105 µL into the chip, air will form a big bubble that can expel the small bubbles, and then, the big bubble can be expelled by the following flushing solution.
10. Load 100 µL of the 50% annealing buffer into the chip loading well. Repeat this loading step for a total of 3 times.
11. Add 6 µL of the sequencing enzyme into 60 µL of the 50% annealing buffer into a new 1.5 mL tube. Mix by pipetting up and down. Load 65 µL of this mixed solution into the chip loading well. Pipette slowly to avoid foaming.
12. Keep the chip away from light and incubate at RT for 5 min.
13. After the incubation, immediately load the chip onto the sequencer and click Start the sequencing run on the screen to start sequencing.
  NOTE: The sequencing raw data and quality control files will be uploaded automatically to the company for data analysis.

Representative Results

Based on this modified protocol, the semiconductor sequencing platform was for the first time, applied for PGT-A. We tested on biopsies from both cleavage-stage blastomeres and blastocyst-stage embryos. It is suggested that the biopsied cells undergo WGA as soon as possible to prevent any degradation of DNA. A previous study compared the performance of different WGA methods and indicated that the method we described here had the best uniformity at the bin size of 100 KB²⁰. Considering the performance of both uniformity and median absolute pairwise difference (MAPD)²¹, this WGA method was chosen for PGT-A using the semiconductor sequencer. Through a retrospective statistical analysis on 186 cleavage stage and 1135 blastocyst stage embryos, we observed that the WGA success rates were 95.4% in blastomere samples and 96.9% in blastocyst samples (Figure 1). The purification step before library construction as a size selection procedure was crucial for sequencing quality by capturing large DNA fragments. Additionally, it facilitated the input amount of 300 ng for library construction. The enzymatic fragmentation method enabled an efficient shearing of WGA products into approximately 160 bp.

Data analysis was conducted using the Euclidean distance and circular binary segmentation (EDCBS) analysis system. In-house validation was performed to evaluate the robustness of this bioinformatic algorithm. We established a reference database exclusive for PGT-A through sequencing 379 WGA products from 66 cell lines with known karyotypes by analyzing a bin size of 100 KB. From this database, a reference range was delineated as the threshold for copy number variant (CNV) calling and 10 MB was set as the cutoff for the detection level. Both sensitivity and specificity reached over 99% at this threshold (Table 1). In the application for PGT-A on embryo biopsies, the window size was set to 400 KB with a sliding window approach to reach enough reads. Quality control (QC) of each sample was determined by unique reads, MAPD and standard deviation of copy number variant (CNV∙SD). Sample beyond one of the three indexes was defined as QC failure (Figure 2C). Interpretation of chromosome scatter plots (Figure 2A,B,D) was conducted by qualified geneticists following a workflow by comparing the identified CNV to DECIPHER, DGV, or ClinGen databases. Individual discrepancies were controlled by an expert curation procedure. Chromosomal abnormalities were grouped into aneuploidy and mosaicism in blastocyst samples. A copy number gain or loss within the range of 30%−70% was classified as carrying mosaic chromosomal composition; otherwise, the result would be interpreted as either euploidy or aneuploidy. In this study, the euploid rates were 45.2% in blastomeres and 52.3% in blastocysts, which echoed to published data²²^,²³.

Figure 1: Demographic statistics of 1321 embryo biopsies tested by this method. (A) Data from 186 cleavage-stage embryos. (B) Data from 1135 blastocyst-stage embryos. WGA success rates are over 95% in both types of specimens. Sequencing quality control failure rates are 3.4% in the cleavage-stage group and only 1.9% in the blastocyst-stage group. Please click here to view a larger version of this figure.

Figure 2: Representative results of PGT-A clinical application of embryo for the 23 pairs of chromosomes. Representative results of (A) euploidy; (B) aneuploidy (seq[GRCh37] (2)x3, (21)x3); (C) sequencing QC failed sample due to CNV∙SD at 0.6571 (acceptance ≤ 0.4); (D) segmental mosaic deletion (55%) of 4p16.3p15.1 (29.50 MB). Please click here to view a larger version of this figure.

	CNV threshold value
	(-0.23, 0.20)	(-0.32, 0.26)	(-0.41, 0.32)	(-0.51, 0.37)	(-0.62, 0.43)	(-0.73, 0.48)
Sensitivity	100.00%	100.00%	100.00%	100.00%	98.30%	96.02%
Specificity	72.41%	81.03%	91.38%	99.10%	99.54%	100.00%

Table 1: Sensitivity and specificity between different Log R ratios by the semiconductor sequencer. A total of 240 samples with known euploid karyotype results were tested by this method and called at different Log R ratios.

Discussion

Different from other sequencing chemistries, the sequencer described here uses semiconductor for the detection of nucleotides. The chip itself is an electronic device that detects hydrogen ions by polymerase-driven base incorporation¹⁷, which enables 2−4 h sequencing time of the Proton program. Besides, the chip is a microwell chip that allows the localization of one target molecule, which is different from the flow cell sequencing chemistry by other sequencer providers. This protocol is a modified protocol optimized for the application of PGT-A. The optimization includes fragmentation of amplified DNA by the enzymatic method instead of sonication to reduce the chance of contamination as well as the size-selection and the PCR system for better performance with lower costs. Additionally, in the clinical setting, we used a validated in-house pipeline for variant calling.

There are critical steps to be aware of during the practice. Ethanol for purification needs to be freshly prepared before the experiment, as a high concentration of ethanol would cause insufficient wash of contaminated DNA while a low concentration would cause loss of target DNA. The fluorometer has to be calibrated by the positive control with a known concentration to ensure the accuracy. Besides, an adequate loading of the template is crucial for sequencing. Bubbles of the right size help to push the template sphere to fall into microwells, but too large bubbles may cause inadequate loading. Users can modify the number of samples (not necessarily 24) to be sequenced for each run. There are 96 indexes designed for this chip. But sequencing read depth will decrease with increasing samples per chip. One of the most common problems is low library concentration, which can be attributed to a low or poor-quality DNA output from purification due to residual ethanol or magnetic beads, or the cracking of beads as previously mentioned. A suboptimal DNA output may also result from low efficiency of PCR, which can be corrected by cautious preparation of the master mix with accurate sample inputs and temperature check of the thermal cyclers. For sequencing QC-failed samples, such as those with high CNV∙SD values (Figure 2C), it is recommended to run the samples on a bioanalyzer for size distribution analysis.

One of the limitations of this method is its higher false single-nucleotide calling rate compared to other platforms. The error rate is 1% compared to only 0.1% indel false positive rate by other sequencers¹⁷. However, this is not a determining factor for CNV calling or PGT-A analysis. Compared to other platforms, application of the emulsion system minimizes operative discrepancies and pipetting errors, increasing the library quality. This is a significant advantage of our method compared to other platforms because the dsDNA concentration is very low and an accurate quantification is required for the following library pooling. Our method introduced the calibration of fluorometer quantification using a standard positive control to control detection error.

As a high throughput platform with short turnaround time, the semiconductor sequencer is ideal for PGT-A and can be widely applied to IVF patients with PGT-A clinical indications such as advanced maternal age²⁴. Deleye et al. conducted parallel sequencing of human blastocysts to compare the performance of the semiconductor sequencer with other sequencers²⁵. Moreover, this PGT-A kit has obtained the “special approval procedure on innovative medical devices” from the China Food and Drug Administration and has been clinically used for thousands of embryos. In terms of cost, the price of this platform is half the price per giga bases compared to another commonly used platform in the PGT-A market. The trophectoderm cells can reliably represent the genetic constitution of the embryo²⁶. This method can potentially be developed for PGT for monogenic/single gene diseases (PGT-M) as Treff et al. have demonstrated²⁷. In their model, they facilitated 300 MB to 1 GB throughput on PGT-M of 16 embryo biopsies and compared the results to two conventional PGT-M methods. By capturing and loading 16 samples, their method reached at least 100x read depth of the targeted region and resulted in 100% reliability and reproducibility²⁷. The throughput of the semiconductor sequencer by our protocol can reach 15 GB and there are 96 barcodes designed; therefore, if applied to targeted PGT-M, a considerable number of embryo biopsies can be sequenced by one chip at a high read depth.

Disclosures

The authors have nothing to disclose.

Acknowledgements

This study was supported by the General Research Fund (Ref No. 14162417) from Hong Kong, the National Natural Science Foundation of China (Ref No. 81860272), the Major Research Plan of the Provincial Science and Technology Foundation of Guangxi (Ref No. AB16380219), and the China Postdoctoral Science Foundation Grant (Ref No. 2018M630993) from China.

Materials

PCR tubes, 0.2 mL	Axygen	PCR-02D-C
UltraPure 0.5M EDTA, pH 8.0	ThermoFisher	15575020
PBS, pH 7.4, Ca²⁺ and Mg²⁺ free	ThermoFisher	10010023
1.0 M NaOH (1.0N) solution	SIGMA-ALDRICH	S2567	For Melt-off solution. Molecular grade
Eppendorf LoBind Tubes, 1.5 mL	Fisher Scientific	13-698-791
Ion Plus Fragment Library Kit	ThermoFisher	4471252
ELGA PURELAB Flex 3 Water Purification System or Equivalent 18 MΩ water system	ThermoFisher	4474524
Ion Plus Fragment Library Kit	ThermoFisher	4471252
PicoPLEX WGA Amplification buffer	Rubicon Genomics	R30050	This can be replaced by SurePlex DNA Amplification System,catalog number: PR-40-415101-03.
PicoPLEX WGA Amplification enzyme	Rubicon Genomics	R30050	This can be replaced by SurePlex DNA Amplification System,catalog number: PR-40-415101-03.
Ion OneTouch Amplification Plate			In kit: Ion OneTouch 2 Supplies (Part No. A26367). Extended kit component in Sheet 5
Ion PI Annealing Buffer
MyOne Beads Capture Solution
Agilent 2100 Bioanalyzer instrument	Agilent	G2939AA
Ion OneTouch Breaking Solution (black cap)			In kit: Ion PI Hi‑Q OT2 Solutions 200 (Part No. A26429). Extended kit component in Sheet 5
Dynabeads MyOne Streptavidin C1	ThermoFisher	65001
PicoPLEX WGA Cell extraction buffer	Rubicon Genomics	R30050	This can be replaced by SurePlex DNA Amplification System,catalog number: PR-40-415101-00.
PicoPLEX WGA Cell extraction enzyme	Rubicon Genomics	R30050	This can be replaced by SurePlex DNA Amplification System,catalog number: PR-40-415101-03.
Ion PI Chip Kit v3	ThermoFisher	A26771
Ion Chip Minifuge, 230 V	ThermoFisher	4479673
Ion PI dATP	ThermoFisher	A26772
Ion PI dCTP	ThermoFisher	A26772
Ion PI dGTP	ThermoFisher	A26772
Ion Plus Fragment Library Kit	ThermoFisher	4471252
Ion Plus Fragment Library Kit	ThermoFisher	4471252
ThermoQ–Temperature Dry Bath	TAMAR	HB-T2-A
NEBNext dsDNA Fragmentase	New England Biolabs	M0348L
NEBNext dsDNA Fragmentase	New England Biolabs	M0348L
Ion PI dTTP	ThermoFisher	A26772
Ion OneTouch 2 Instrument	ThermoFisher	INS1005527	ThermoFisher Catalog number: 4474778.
Ion Plus Fragment Library Kit	ThermoFisher	4471252
Ion One Touch ES	ThermoFisher	8441-22	ThermoFisher Catalog number: 4469495. Extended kit component in Sheet 5
Ethanol	SIGMA-ALDRICH	51976	This can be replaced by any brand's molecular grade absolute ethanol.
PicoPLEX WGA Extraction enzyme dilution buffer	Rubicon Genomics	R30050	This can be replaced by SurePlex DNA Amplification System,catalog number: PR-40-415101-01.
PicoPLEX WGA Extraction enzyme dilution buffer	Rubicon Genomics	R30050	This can be replaced by SurePlex DNA Amplification System,catalog number: PR-40-415101-02.
Qubit 3.0 Fluorometer	ThermoFisher	Q33216	This model has been replaced by Qubit 4 Fluorometer, Catalog number: Q33226.
Qubit ds DNA HS Assay kit	ThermoFisher	M2002-02
Qubit Assay Tubes	ThermoFisher	Q32856
Ion PI Foaming Solution	ThermoFisher	A26772
Index for barcoding of libraries	BaseCare		this is a in-house prepared index. Users can buy commercial product from ThermoFisher Ion Xpress Barcode Adapters Kits (Cat. No. 4474517)
Ion PI Loading Buffer	ThermoFisher	A26772
Solid(TM) Buffer Kit-1X Low TE Buffer	ThermoFisher	4389764
Agencour AMPure XP Kit	Beckman Coulter	A63880
DynaMag-2 magnet (magnetic rack)	ThermoFisher	12321D
Ion PI Master Mix PCR buffer
Sorvall Legend Micro 17 Microcentrifuge	Micro 17	75002430
Ion Plus Fragment Library Kit	ThermoFisher	4471252
Nuclease-free water	ThermoFisher	AM9922	This can be replaced by other brand.
PicoPLEX WGA Nuclease-free water	Rubicon Genomics	R30050	This can be replaced by SurePlex DNA Amplification System,catalog number: PR-40-415101-03.
Ion OneTouch Oil bottle			Ion PI Hi‑Q OT2 Solutions 200 (Part No. A26429). Extended kit component in Sheet 5
Ion Plus Fragment Library Kit	ThermoFisher	4471252	Extended kit component in Sheet 3
double-strand DNA standard			This is a in-house prepared DNA standard for calibration of Qubit before quantification of library.
PicoPLEX WGA Preamplification buffer	Rubicon Genomics	R30050	This can be replaced by SurePlex DNA Amplification System,catalog number: PR-40-415101-03.
PicoPLEX WGA Preamplification enzyme	Rubicon Genomics	R30050	This can be replaced by SurePlex DNA Amplification System,catalog number: PR-40-415101-03.
Library Amplification Primer Mix	ThermoFisher	4471252	Extended kit component in Sheet 3
Ion OneTouch Reaction Filter			Extended kit component in Sheet 5
Recovery Router			Extended kit component in Sheet 5
Recovery Tubes			Extended kit component in Sheet 5
ISP Resuspension Solution
Ion Proton	ThermoFisher	DA8600	This model is imported by Da An Gene Co.,LTD. of Sun Yat-Sen University from ThermoFisher and has been certified by China Food and Drug Administration for clinical application. The catalog number in ThermoFisher is 4476610.
Ion PI Hi‑Q Sequencing Polymerase	ThermoFisher	A26772
Ion PI Sequencing Primer
server for sequencer	Lenovo	T260
Ion PI Sphere Particles
Platinum PCR SuperMix High Fidelity	ThermoFisher	4471252
Nalgene 25mm Syringe Filters	ThermoFisher	724-2045	Pore size: 0.45μm. Specifically for aqueous fluids.
Ion PI Hi‑Q W2 Solution	ThermoFisher	A26772
Ion PI 1X W3 Solution	ThermoFisher	A26772
Ion OneTouch Wash Solution C1
The Ion PGM Hi‑Q View Sequencing Kit	ThermoFisher	A30044	Extended kit component in Sheet 2
Ion Plus Fragment Library Kit	ThermoFisher	4471252	Extended kit component in Sheet 3
Ion PI Hi-Q Sequencing 200 Kit (1 sequencing run per initialization)	ThermoFisher	A26772	Extended kit component in Sheet 4
Ion PI Hi‑Q OT2 200 Kit	ThermoFisher	A26434	Extended kit component in Sheet 5

References

Balaban, B., Urman, B. Effect of oocyte morphology on embryo development and implantation. Reproductive BioMedicine Online. 12 (5), 608-615 (2006).
Capalbo, A., et al. Correlation between standard blastocyst morphology, euploidy and implantation: An observational study in two centers involving 956 screened blastocysts. Human Reproduction. 29 (6), 1173-1181 (2014).
Magli, M. C., Gianaroli, L., Ferraretti, A. P. Chromosomal abnormalities in embryos. Molecular and Cellular Endocrinology. 183, 29-34 (2001).
Trussler, J. L., Pickering, S. J., Ogilvie, C. M. Investigation of chromosomal imbalance in human embryos using comparative genomic hybridization. Reproductive BioMedicine Online. 8 (6), 701-711 (2004).
Fragouli, E., et al. Cytogenetic analysis of human blastocysts with the use of FISH, CGH and aCGH: Scientific data and technical evaluation. Human Reproduction. 26 (2), 480-490 (2011).
Calhaz-Jorge, C., et al. Assisted reproductive technology in Europe, 2013: Results generated from European registers by ESHRE. Human Reproduction. 32 (10), 1957-1973 (2017).
Dyer, S., et al. International committee for monitoring assisted reproductive technologies world report: Assisted reproductive technology 2008, 2009 and 2010. Human Reproduction. 31 (7), 1588-1609 (2008).
Dahdouh, E. M., Balayla, J., García-Velasco, J. A. Comprehensive chromosome screening improves embryo selection: A meta-analysis. Fertility and Sterility. 104 (6), 1503-1512 (2015).
Chen, M., Wei, S., Hu, J., Quan, S. Can Comprehensive Chromosome Screening Technology Improve IVF/ICSI Outcomes? A Meta-Analysis. PloS One. 10 (10), e0140779 (2015).
Northrop, L. E., Treff, N. R., Levy, B., Scott, J. T. SNP microarray-based 24 chromosome aneuploidy screening demonstrates that cleavage-stage FISH poorly predicts aneuploidy in embryos that develop to morphologically normal blastocysts. Molecular Human Reproduction. 16 (8), 590-600 (2010).
Barbash-Hazan, S., et al. Preimplantation aneuploid embryos undergo self-correction in correlation with their developmental potential. Fertility and Sterility. 92 (3), 890-896 (2009).
Fragouli, E., et al. Comprehensive cytogenetic analysis of the human blastocyst stage. Fertility and Sterility. 90 (11), S36 (2008).
Fiorentino, F., et al. Development and validation of a next-generation sequencing-based protocol for 24-chromosome aneuploidy screening of embryos. Fertility and Sterility. 101 (5), 1375-1382 (2014).
Fiorentino, F., et al. Application of next-generation sequencing technology for comprehensive aneuploidy screening of blastocysts in clinical preimplantation genetic screening cycles. Human Reproduction. 29 (12), 2802-2813 (2014).
Wells, D., et al. Clinical utilisation of a rapid low-pass whole genome sequencing technique for the diagnosis of aneuploidy in human embryos prior to implantation. Journal of Medical Genetics. 51 (8), 553-562 (2014).
Quail, M. A., et al. A tale of three next generation sequencingplatforms: comparison of Ion Torrent, PacificBiosciences and Illumina MiSeq sequencers. BMC Genomics. 13 (1), 1-13 (2012).
Goodwin, S., McPherson, J. D., McCombie, W. R. Coming of age: ten years of next-generation sequencing technologies. Nature Reviews Genetics. 17 (6), 333-351 (2016).
Bono, S., et al. Validation of a semiconductor next-generation sequencing-based protocol for preimplantation genetic diagnosis of reciprocal translocations. Prenatal Diagnosis. 35 (10), 938-944 (2015).
Harton, G. L., et al. ESHRE PGD Consortium/Embryology Special Interest Groupbest practice guidelines for polar body and embryo biopsy for preimplantation genetic diagnosis/screening (PGD/PGS). Human Reproduction. 26 (1), 41-46 (2011).
Liu, W. Q., et al. The performance of MALBAC and MDA methods in the identification of concurrent mutations and aneuploidy screening to diagnose beta-thalassaemia disorders at the single- and multiple-cell levels. Journal of Clinical Laboratory Analysis. 32 (2), 1-8 (2018).
Zhang, X., et al. The comparison of the performance of four whole genome amplification kits on ion proton platform in copy number variation detection. Bioscience Reports. 37 (4), BSR20170252 (2017).
Munné, S., Grifo, J., Wells, D. Mosaicism: “survival of the fittest” versus “no embryo left behind”. Fertility and Sterility. 105 (5), 1146-1149 (2016).
Del Carmen Nogales, M., et al. Type of chromosome abnormality affects embryo morphology dynamics. Fertility and Sterility. 107 (1), 229-235 (2017).
Harton, G. L., et al. ESHRE PGD consortium best practice guidelines for amplification-based PGD. Human Reproduction. 26 (1), 33-40 (2011).
Deleye, L., et al. Shallow whole genome sequencing is well suited for the detection of chromosomal aberrations in human blastocysts. Fertility and Sterility. 104 (5), 1276-1285 (2015).
Bielanska, M., Tan, S. L., Ao, A. Chromosomal mosaicism throughout human preimplantation development in vitro: incidence, type, and relevance to embryo outcome. Human Reproduction. 17 (2), 413-419 (2002).
Treff, N. R., et al. Evaluation of targeted next-generation sequencing-based preimplantation genetic diagnosis of monogenic disease. Fertility and Sterility. 99 (5), 1377-1384 (2013).

Play Video

PDF

DOI

DOWNLOAD MATERIALS LIST

Cite This Article

Gui, B., Zhang, Y., Liang, B., Kwok, Y. K. Y., Lui, W. T., Yeung, Q. S. Y., Kong, L., Xuan, L., Chung, J. P. W., Choy, K. W. Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy. J. Vis. Exp. (150), e59273, doi:10.3791/59273 (2019).